All Deals
May 15, 2025 - Deals
Brellium Secures $16.7 Million Series A Funding Led By First Round Capital And Left Lane Capital
Brellium, an AI-powered startup co-founded by Zach Rosen, has raised $16.7 million in Series A funding led by First Round Capital and Left Lane Capital, with participation from Menlo Ventures and others. Motivated by Rosen’s personal experience with a costly medical misdiagnosis caused by documentation gaps, Brellium automates clinical chart reviews to ensure compliance with payer and billing standards. The platform now supports 250,000 providers nationwide across specialties like behavioral health, hospice, and chronic care. The new funding will support team expansion, product development, and broader adoption across the healthcare industry.
INVESTORS: First Round Capital, Left Lane Capital, Menlo Ventures, Digital Health Venture Partners, Kearny Jackson, Necessary Ventures, Andrew Adams, Steven Gutentag, Demetri Karagas, Cory Levy & Fiat Ventures
ROUND: Series A
AMOUNT: $16,700,000
HQ: #NewYork #NY #NewYorkCity #NYC
#VentureCapital #Brellium #ZachRosen #FirstRoundCapital #LeftLaneCapital #MenloVentures #DigitalHealthVenturePartners #KearnyJackson #NecessaryVentures #AndrewAdams #StevenGutentag #DemetriKaragas #CoryLevy #FiatVentures #TradedVC
More Deals
View All
Colossal Biosciences In Talks For Funding Round Targeting $23 Billion ValuationColossal Biosciences, the de-extinction biotech startup known for its efforts to recreate the woolly mammoth and other extinct species, is reportedly in talks to raise new funding at a valuation of roughly $23 billion–$24 billion, according to Axios. The potential raise would mark a significant jump for the five-year-old company, with investors valuing not only its genetic-engineering programs but also its broader genomics, reproductive technology, conservation, and intellectual property platform. Colossal has begun generating revenue through conservation technology sales and technology spinouts, including Astromech, an AI-driven predictive modeling company, and Form Bio, a computational biology platform, expanding its value beyond de-extinction efforts.
FOUNDERS: Ben Lamm & George Church
TARGET VALUATION: $23,000,000,000
HQ: Dallas, Texas
#VentureCapital #ColossalBiosciences #BenLamm #GeorgeChurch #TradedVC